Skip to main content

Table 1 Description of liver dysfunction between survivors and non-survivors among included studies

From: A meta-analysis of the impact of COVID-19 on liver dysfunction

Study, year Setting Country Sample (dead/alive) Age (dead/alive) Chronic liver disease (dead/alive) ALT (dead/alive) AST (dead/alive) Female gender NOS
Yang et al. [7], 2020 ICU China 32/20 64.6 (11.2)/51.9 (12.9) NA NA NA 11/6 7
Wang et al. [13], 2020 Isolation ward China 65/274 76 (70–83)/68 (64–74) 1/1 24 (19–49)/28 (17–43) 43 (30–68)/29 (22–43) 26/147 7
Chen N et al. [14], 2020 Isolation ward China 113/161 68.0(62.0–77.0)/51.0(37.0–66.0) 5/6 (HBsAg +) 28.0 (18.0–47.0)/ 20.0 (14.8–32.0) 45.0 (31.0–67.0)/ 25.0 (20.0–33.3) 30/73 8
Zhou et al. [16] 2020 Isolation ward China 54/135 69·0 (63·0–76·0)/52·0 (45·0–58·0) NA 40.0 (24.0–51.0)/27.0 (15.0–40.0) NA 16/56 7
Du et al. [15], 2020 Isolation ward China 21/158 70.2(7.7)/56.0(13.5) 2/2 27.0 (20.0‒37.0)/22.0 (14.0‒40.5) 40.0 (27.0‒61.5)/27.5 (19.0‒42.0) 11/71 7
  1. Data expressed by mean (SD) or median (IQR), IQR interquartile range, ICU intensive care unit, ALT alanine aminotransferase (> 41 U/L), AST aspartate aminotransferase (> 40 U/L), HBsAg Hepatitis B virus surface antigen positivity